Join the Oncology Voice Network. Join for Free
MSL Certification Programs: To Cert or Not to Cert?
MSL certification BCMAS credential MSL-BC program BC-MSL certification Medical Science Liaison training

MSL Certification Programs: To Cert or Not to Cert?


Share This Article


Summary

In this episode, Tom Caravela delves into the world of certification programs for Medical Science Liaisons (MSLs). He provides an overview of popular certifications like BCMAS and MSL-BC, as well as the BC-MSL certification from FSTP. Tom discusses the significance of these programs and how they can enhance the credibility and career prospects of MSLs. He also shares valuable resources for those considering certification and offers closing advice on making the most of these opportunities. The episode wraps up with a reminder to share the podcast and subscribe for future insights.

By request, this episodes breaks down the different MSL certification programs.

Learn…

👉 Who is eligible for which certification program

👉 What costs are associated

👉 How the programs are administered

👉 Why you may want to consider a certification

Click for Source
MSL certification, BCMAS credential, MSL-BC program, BC-MSL certification, Medical Science Liaison training

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The ULTIMATE Checklist for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Samantha Buckley

The ULTIMATE Checklist for New MSLs

Podcast
Repackage what you have for what you want
Partner Avatar MSL Talk: Tom Caravela, Cherie Hyder

Repackage what you have for what you want

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN